Abstract
To supplement both the FDA and EMA guidance, we describe the principles and key elements for developing a DMC chart for individual clinical trials affected by COVID-19.
| Original language | American English |
|---|---|
| Journal | |
| State | Published - Apr 21 2020 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Disciplines
- Biostatistics
- Environmental Public Health
- Epidemiology
- Public Health
Fingerprint
Dive into the research topics of 'Statistical Considerations for Clinical Trials During COVID-19: Independent DMC for Blinded Data Monitoring and Analysis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver